The rationale for possible targeted therapies in CMTC
Schematic illustration of the rationale for possible targeted therapies in CMTC. Blocking the constitutive activation of the Wnt/β-catenin signaling pathway could play an essential role in the treatment of CMTC through the degradation of β-catenin by stabilizing Axin2 (tankyrase inhibitors), CK1 agonists (SSTC3), inhibitors targeting β-catenin-TFC transcription complex (LF3), CBP inhibitors, as well as porcupine inhibitors, but data on clinical efficacy and safety are still insufficient. E2 via ER would have a tumor-promoting role through the PI3K/AKT/mTOR and the RAS/RAF/MAPK signaling pathways, which would justify treatment with both antiestrogens (tamoxifen and aromatase inhibitors) and MKI inhibitors. The detection of additional somatic events (e.g. RET rearrangements) could be subsidiary to treatment with specific inhibitors. CMTC, morular cribriform thyroid carcinoma; E2, estrogens; ER, estrogen receptors; MKI, multikinase; TCF/LEF, T-cell factor/lymphoid enhancer factor; CTNNB1, β-catenin 1; CCND1, cyclin D1; APC, APC regulator of WNT signaling pathway; CK1, casein kinase 1; GSK3β, glycogen synthase kinase 3β; DVL, disheveled; CBP, cyclic adenosine monophosphate responsive element binding protein 1 binding protein; LRP5/6, low-density lipoprotein receptor-related protein 5/6; PI3K, phosphatidylinositol 3-kinase, AKT, serine/threonine kinase; mTOR, mechanistic target of rapamycin kinase; RAS, small GTPase; RAF, Raf-1 proto-oncogene, serine/threonine kinase; MAPK, mitogen-activated protein kinase
Publication
Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review) (2024) Soledad Cameselle-García, et al. Oncol Rep. 2024 Sep;52(3). Figure: F4.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | DVL | DVL | ncbigene_synonym | DVL1 | 1855 |
| Homo sapiens | Primates | DVL | DVL | ncbigene_synonym | DVL1P1 | 8215 |
| Homo sapiens | Primates | DVL | DVL | famplex_relations | DVL2 | 1856 |
| Homo sapiens | Primates | DVL | DVL | famplex_relations | DVL3 | 1857 |
| Homo sapiens | Primates | Axin1 | AXIN1 | ncbigene_symbol | AXIN1 | 8312 |
| Homo sapiens | Primates | CK1 | CK1 | ncbigene_synonym | CSNK1A1 | 1452 |
| Homo sapiens | Primates | CK1 | CK1 | ncbigene_synonym | KRT1 | 3848 |
| Homo sapiens | Primates | CK1 | CK1 | ncbigene_synonym | CSNK1A1L | 122011 |
| Homo sapiens | Primates | APC | APC | ncbigene_symbol | APC | 324 |
| Homo sapiens | Primates | APC | APC | ncbigene_synonym | PROC | 5624 |
| Homo sapiens | Primates | GSK3ẞ | GSK3 | famplex_relations | GSK3A | 2931 |
| Homo sapiens | Primates | GSK3ẞ | GSK3 | famplex_relations | GSK3B | 2932 |
| Homo sapiens | Primates | PTEN | PTEN | ncbigene_symbol | PTEN | 5728 |
| Homo sapiens | Primates | PORCN | PORCN | ncbigene_symbol | PORCN | 64840 |
| Homo sapiens | Primates | mTOR | MTOR | ncbigene_symbol | MTOR | 2475 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | KRAS | 3845 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | HRAS | 3265 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | NRAS | 4893 |
| Homo sapiens | Primates | GTP | GTP | ncbigene_synonym | MTG1 | 92170 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CA | 5290 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CB | 5291 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CD | 5293 |
| Homo sapiens | Primates | PI3K | PI3K | ncbigene_synonym | PIK3CG | 5294 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R3 | 8503 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R4 | 30849 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R5 | 23533 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R6 | 146850 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R1 | 5295 |
| Homo sapiens | Primates | PI3K | PI3K | famplex_relations | PIK3R2 | 5296 |
| Homo sapiens | Primates | RET | RET | ncbigene_symbol | RET | 5979 |
| Homo sapiens | Primates | BRAF | BRAF | ncbigene_symbol | BRAF | 673 |
| Homo sapiens | Primates | MEK | MEK | ncbigene_synonym | MAP2K7 | 5609 |
| Homo sapiens | Primates | MEK | MEK | famplex_relations | MAP2K1 | 5604 |
| Homo sapiens | Primates | MEK | MEK | famplex_relations | MAP2K2 | 5605 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | EPHB2 | 2048 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | MAPK1 | 5594 |
| Homo sapiens | Primates | ERK | ERK | famplex_relations | MAPK3 | 5595 |
| Homo sapiens | Primates | CBP | CBP | ncbigene_synonym | CREBBP | 1387 |
| Homo sapiens | Primates | CBP | CBP | ncbigene_synonym | EIF4E | 1977 |
| Homo sapiens | Primates | CBP | CBP | ncbigene_synonym | OPN1LW | 5956 |
| Homo sapiens | Primates | CBP | CBP | ncbigene_synonym | PAG1 | 55824 |
| Homo sapiens | Primates | CBP | CBP | ncbigene_synonym | PCBP4 | 57060 |
| Homo sapiens | Primates | TCF/LEF | TCF | ncbigene_synonym | HNF4A | 3172 |
| Homo sapiens | Primates | MYC | MYC | ncbigene_symbol | MYC | 4609 |
| Homo sapiens | Primates | CCND1 | CCND1 | ncbigene_symbol | CCND1 | 595 |
| Homo sapiens | Primates | STAT3 | STAT3 | ncbigene_symbol | STAT3 | 6774 |
| Homo sapiens | Primates | ELK1 | ELK1 | ncbigene_symbol | ELK1 | 2002 |
| Homo sapiens | Primates | ELK1 | ELK1 | ncbigene_synonym | KCNH4 | 23415 |
| Homo sapiens | Primates | ELK1 | ELK1 | ncbigene_synonym | KCNH8 | 131096 |
| Homo sapiens | Primates | FOS | FOS | ncbigene_symbol | FOS | 2353 |
| Homo sapiens | Primates | FOS | FOS | famplex_relations | FOSB | 2354 |
| Homo sapiens | Primates | FOS | FOS | famplex_relations | FOSL1 | 8061 |
| Homo sapiens | Primates | FOS | FOS | famplex_relations | FOSL2 | 2355 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Tamoxifen | tamoxifen | 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine | chebi:41774 | |
| Aromatase inhibitors | aromatase inhibitors | chebi:50790 | ||
| inhibitors | inhibitors | inhibitor | chebi:35222 | |
| inhibitors | inhibitors | inhibitor | chebi:35222 | |
| MEK | MEK | butan-2-one | chebi:28398 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|